AGM/EGMMay 28, 2026, 09:07 AM
Vir Biotechnology Director Departs; New Audit Chair Appointed; AGM Results
AI Summary
Vir Biotechnology announced that Saira Ramasastry departed from its Board of Directors and as Chair of the Audit Committee due to a business conflict, effective May 26, 2026. Following her departure, Robert More was appointed as the new Chair of the Audit Committee, and the Board size was reduced from eight to seven members. Additionally, at its 2026 Annual Meeting of Stockholders, the company's stockholders elected three Class I directors, approved executive compensation on an advisory basis, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026.
Key Highlights
- Saira Ramasastry stepped down from Vir Biotechnology's Board and Audit Committee effective May 26, 2026, due to a business conflict.
- Robert More was appointed Chair of the Audit Committee, effective upon Ms. Ramasastry's departure.
- The Board size was decreased from eight to seven members, effective May 26, 2026.
- Stockholders elected Robert More, Janet Napolitano, and Elliott Sigal as Class I directors until the 2029 Annual Meeting.
- The advisory vote on executive compensation was approved by stockholders with 108,453,963 votes for.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 with 137,048,756 votes for.
Price Impact
More from VIR